Incretin Effects of Branched Chain Amino Acids
Primary Purpose
Glucose Metabolism Disorders
Status
Completed
Phase
Not Applicable
Locations
Czech Republic
Study Type
Interventional
Intervention
IV BCAA
ORAL BCAA
ORAL Placebo
Sponsored by
About this trial
This is an interventional basic science trial for Glucose Metabolism Disorders focused on measuring Insulin response, Incretin effect, GLP-1, GIP, Valine, Leucine, Isoleucine, Branched chain amino acids
Eligibility Criteria
Inclusion Criteria:
- healthy volunteers
Exclusion Criteria:
- age under 18 years, obesity, any chronic disease related to energy metabolism (particularly diabetes, thyreopathy, hypertension, dyslipidemia, atherosclerosis etc.), any chronic medication, smoking and regular alcohol consumption
Sites / Locations
- Centre for Research on Diabetes, Metabolism and Nutrition, 3rd Faculty of Medicine, Charles University in Prague
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
IV BCAA test
ORAL BCAA test
ORAL PLACEBO test
Arm Description
IV application of BCAA solution
At once oral ingestion of BCAA capsules
At once oral ingestion of placebo capsules
Outcomes
Primary Outcome Measures
Area under the plasma concentration versus time curve (AUC) of GLP-1 and GIP
At time 0, 15, 30, 45, 60, 90, 120 min serum levels of GLP-1 and GIP in peripheral blood samples were detected using commercially available ELISA kits
Secondary Outcome Measures
Area under the plasma concentration versus time curve (AUC) of BCAA
at time 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min serum levels of BCAAs in peripheral blood samples were determined by method of capillary electrophoresis (CE) with contactless conductivity detection
Area under the plasma concentration versus time curve (AUC) of insulin
at time 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min serum levels of insulin in peripheral blood samples using solid phase competitive chemiluminescent enzyme immunoassay were detected
Area under the plasma concentration versus time curve (AUC) of glucose
at time 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min serum levels of glucose in peripheral blood samples using using hexokinase reaction were detected
Full Information
NCT ID
NCT02697305
First Posted
February 27, 2016
Last Updated
March 7, 2016
Sponsor
Charles University, Czech Republic
1. Study Identification
Unique Protocol Identification Number
NCT02697305
Brief Title
Incretin Effects of Branched Chain Amino Acids
Official Title
Effect of Intravenously and Orally Administered Branched Chain Amino Acids on Incretin Response
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Charles University, Czech Republic
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Branched chain amino acids (BCAA) are known to exert insulinogenic effect. Whether this effect is mediated by incretins (GLP-1, GIP) is not known. The aim of the study was to show incretin effect of BCAA, i.e. whether the oral administration of BCAA elicits higher insulin and incretin response when compared with IV route of the same dose of BCAA. Eighteen healthy, male subjects participated in three tests: IV application of BCAA solution (30.7±1.1 g of BCAA, IV BCAA) second was oral ingestion of BCAA capsules in the same dose (ORAL BCAA) and third experiment was oral placebo (PLACEBO). Glucose, insulin, GLP-1, GIP, valine, leucine and isoleucine levels were measured at time interval for up to 4 h.
Detailed Description
Study protocols: Three tests were conducted on a different occasion (at least 7 days in between). First test (IV BCAA test) comprised of IV application of BCAA solution (Nutramin VLI 3%, Fresenius Kabi, KGaA, Germany; Leucine 43%, Isoleucine 24%, Valine 33%) in total dose of 0,4 g/kg in a 2 h infusion (mean solution volume 1023±34.6mL, mean total dose of BCAA 30.7±1.1g) to respect maximum recommended infusion rate. Second test (ORAL BCAA test) comprised of at once oral ingestion of BCAA capsules (BCAA capsules, Reflex Nutrition, UK, Brighton; Leucine 50%, Isoleucine 25%, Valine 25%) in a single dose of 0.4g/kg (mean total dose of BCAA 30.7±1.1 g) administered over 30s, washed down with 500mL of tap water. Third test (ORAL PLACEBO test) comprised of at once oral ingestion of placebo capsules (methylcellulose, University hospital institution pharmacy prepared) in a single dose of 0.4 g/kg administered over 30 s, washed down with 500 mL of tap water. The content of placebo capsules was weighted and packed identically with BCAA capsules. Nor participants nor the staff administering capsules and carrying out the protocol did not know about capsules content so that randomized double-blinded settings could have been maintained.
Blood analysis: Basal peripheral venous blood was drawn from each subject after 12 h of fasting (-15 min) and then at time 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min throughout the intervention. Plasma was immediately separated and all samples were frozen at -80 °C until analysis were performed. For GLP-1 and GIP analysis BD P800 Blood Collection System was used with coat developed to preserve metabolic peptides in blood (cocktail of proteases, esterase and DPP-IV inhibitors, anticoagulant 3,6 mg di-potassium ethylenediaminetetraacetic acid (K2EDTA), Becton, Dickinson and Co., New Jersey, USA).
Parameters of glucose homeostasis were assessed: plasma glucose using hexokinase reaction (Konelab Glucose analyzer, Thermo Fisher Scientific, Oy., Finland) and serum insulin using solid phase competitive chemiluminescent enzyme immunoassay (Immulite 2000, Siemens A.G., Germany).
Commercially available ELISA kits were used for GLP-1 and GIP analysis: for GLP-1 Immuno-Biological Laboratories (Immuno-Biological Laboratories, Gunma, Japan) and for GIP Millipore (EMD Millipore Corporation, Bilerica, MA, USA).
Serum levels of BCAAs were determined by method of capillary electrophoresis (CE) with contactless conductivity detection, which has been already described in details [18]. Shortly: CE measurements were carried out using HP3DCE system (Agilent Technologies, Waldbronn, Germany) equipped with a built-in contactless conductivity detector. Separation took place in a fused-silica capillary (31.4 cm in total length, 14.7 cm to detector, 25 μm inside diameter, 363 μm outside diameter, Composite Metal Services, UK) at the controlled temperature of 25 °C. The inner surface of the capillary is covered using INST coating solution (Biotaq, U.S.A.) to prevent electro-osmotic flow before its first use [19]. The CE separation is performed in an optimized background electrolyte with composition 3.2 mol/l acetic acid in 20% v/v methanol, pH 2.0. The achieved separation time was 125 s at electric field intensity of 0.96 kV/cm and simultaneous application of a hydrodynamic pressure of 50 mbar. The separation efficiency in blood serum equaled 461,000 plates/m for valine and isoleucine, and 455,000 plates/m for leucine; the detection limits are equal to 0.4 µM for all three amino acids. The relative standard deviation values for repeatability of the migration time equaled 0.1% for measurements during a single day and 0.3% for measurements on different days; the relative standard deviation values for repeatability of the peak areas equaled 2.3 - 2.6% for measurements during a single day and 2.7 - 4.6% for measurements on different days. Blood samples were collected in test tubes containing ethylenediaminetetraacetic acid (EDTA). The obtained serum samples were stored in a freezer at -20 °C until the analysis. Prior to the analysis, the unfrozen serum samples were deproteinized by mixing 250 µl of serum with 750 µL of acetonitrile. Deproteinization was performed in an Eppendorf tube after shaking for 30s. Then the serum samples were centrifuged at an acceleration of 4 g for 45 s; 800 µL of the obtained supernatant were taken for CE analysis.
Statistical analysis: Data are presented in text, tables and figures as means ± standard error of the mean (SEM) and values of p<0.05 were considered statistically significant. Secretion responses for insulin, GIP, GLP-1, valine, leucine and isoleucine were calculated for each subject as incremental areas under the curve (iAUC). iAUCs calculation allow for different individual baseline values. iAUCs were calculated using the trapezoid model, from 0-240 min for glucose, insulin and BCAA and 0-120 for GLP-1 and GIP. All individual values below the baseline were excluded and each subject in respective study was their own reference. Secretion responses for glucose were calculated as decremental AUC (dAUC) as the response is predominantly negative. All individual values above the baseline were excluded in the case. Data for statistical comparison for iAUC and individual values were tested for normality and for normally distributed data, samples were compared using general linear model ANOVA with Bonferroni's multiple comparison to test the statistical significance of differences between groups. Repeated measures ANOVA test was used to assess time effect for every respective treatment. Mixed model ANOVA was used to assess treatment and time vs treatment effect. Differences between groups were identified using Bonferroni's multiple comparisons tests. GraphPad Prism, release 5.03 (GraphPad software, San Diego) was used to perform all statistical procedures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glucose Metabolism Disorders
Keywords
Insulin response, Incretin effect, GLP-1, GIP, Valine, Leucine, Isoleucine, Branched chain amino acids
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Non-Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IV BCAA test
Arm Type
Experimental
Arm Description
IV application of BCAA solution
Arm Title
ORAL BCAA test
Arm Type
Experimental
Arm Description
At once oral ingestion of BCAA capsules
Arm Title
ORAL PLACEBO test
Arm Type
Placebo Comparator
Arm Description
At once oral ingestion of placebo capsules
Intervention Type
Dietary Supplement
Intervention Name(s)
IV BCAA
Other Intervention Name(s)
Nutramin VLI 3%, Fresenius Kabi, KGaA, Germany
Intervention Description
in total dose of 0,4 g/kg in a 2 h intravenous infusion
Intervention Type
Dietary Supplement
Intervention Name(s)
ORAL BCAA
Other Intervention Name(s)
BCAA capsules, Reflex Nutrition, UK, Brighton
Intervention Description
single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
Intervention Type
Other
Intervention Name(s)
ORAL Placebo
Other Intervention Name(s)
methylcellulose, University Hospital Inst. Pharmacy prepared
Intervention Description
single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
Primary Outcome Measure Information:
Title
Area under the plasma concentration versus time curve (AUC) of GLP-1 and GIP
Description
At time 0, 15, 30, 45, 60, 90, 120 min serum levels of GLP-1 and GIP in peripheral blood samples were detected using commercially available ELISA kits
Time Frame
0-120 min after administration
Secondary Outcome Measure Information:
Title
Area under the plasma concentration versus time curve (AUC) of BCAA
Description
at time 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min serum levels of BCAAs in peripheral blood samples were determined by method of capillary electrophoresis (CE) with contactless conductivity detection
Time Frame
0-240 min after administration
Title
Area under the plasma concentration versus time curve (AUC) of insulin
Description
at time 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min serum levels of insulin in peripheral blood samples using solid phase competitive chemiluminescent enzyme immunoassay were detected
Time Frame
0-240 min after administration
Title
Area under the plasma concentration versus time curve (AUC) of glucose
Description
at time 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min serum levels of glucose in peripheral blood samples using using hexokinase reaction were detected
Time Frame
0-240 min after administration
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
healthy volunteers
Exclusion Criteria:
age under 18 years, obesity, any chronic disease related to energy metabolism (particularly diabetes, thyreopathy, hypertension, dyslipidemia, atherosclerosis etc.), any chronic medication, smoking and regular alcohol consumption
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michal Anděl, Prof., MD
Organizational Affiliation
3rd Faculty of Medicine, Charles University in Prague
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre for Research on Diabetes, Metabolism and Nutrition, 3rd Faculty of Medicine, Charles University in Prague
City
Prague 10
ZIP/Postal Code
100 34
Country
Czech Republic
12. IPD Sharing Statement
Plan to Share IPD
Yes
Citations:
PubMed Identifier
5936455
Citation
Berger S, Vongaraya N. Insulin response to ingested protein in diabetes. Diabetes. 1966 May;15(5):303-6. doi: 10.2337/diab.15.5.303. No abstract available.
Results Reference
background
PubMed Identifier
5919350
Citation
Floyd JC Jr, Fajans SS, Conn JW, Knopf RF, Rull J. Stimulation of insulin secretion by amino acids. J Clin Invest. 1966 Sep;45(9):1487-502. doi: 10.1172/JCI105456. No abstract available.
Results Reference
background
PubMed Identifier
20882645
Citation
Gannon MC, Nuttall FQ. Amino acid ingestion and glucose metabolism--a review. IUBMB Life. 2010 Sep;62(9):660-8. doi: 10.1002/iub.375.
Results Reference
background
PubMed Identifier
15531672
Citation
Nilsson M, Stenberg M, Frid AH, Holst JJ, Bjorck IM. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr. 2004 Nov;80(5):1246-53. doi: 10.1093/ajcn/80.5.1246.
Results Reference
background
PubMed Identifier
16002802
Citation
Frid AH, Nilsson M, Holst JJ, Bjorck IM. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr. 2005 Jul;82(1):69-75. doi: 10.1093/ajcn.82.1.69.
Results Reference
background
PubMed Identifier
20456814
Citation
Pal S, Ellis V. The acute effects of four protein meals on insulin, glucose, appetite and energy intake in lean men. Br J Nutr. 2010 Oct;104(8):1241-8. doi: 10.1017/S0007114510001911. Epub 2010 May 11.
Results Reference
background
PubMed Identifier
12514305
Citation
Layman DK. The role of leucine in weight loss diets and glucose homeostasis. J Nutr. 2003 Jan;133(1):261S-267S. doi: 10.1093/jn/133.1.261S.
Results Reference
background
PubMed Identifier
12163658
Citation
Calbet JA, MacLean DA. Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans. J Nutr. 2002 Aug;132(8):2174-82. doi: 10.1093/jn/132.8.2174.
Results Reference
background
PubMed Identifier
17413098
Citation
Nilsson M, Holst JJ, Bjorck IM. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr. 2007 Apr;85(4):996-1004. doi: 10.1093/ajcn/85.4.996.
Results Reference
background
PubMed Identifier
947963
Citation
Wahren J, Felig P, Hagenfeldt L. Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest. 1976 Apr;57(4):987-99. doi: 10.1172/JCI108375.
Results Reference
background
PubMed Identifier
20500788
Citation
Yang J, Chi Y, Burkhardt BR, Guan Y, Wolf BA. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. Nutr Rev. 2010 May;68(5):270-9. doi: 10.1111/j.1753-4887.2010.00282.x.
Results Reference
background
PubMed Identifier
4700552
Citation
Raptis S, Dollinger HC, Schroder KE, Schleyer M, Rothenbuchner G, Pfeiffer EF. Differences in insulin, growth hormone and pancreatic enzyme secretion after intravenous and intraduodenal administration of mixed amino acids in man. N Engl J Med. 1973 Jun 7;288(23):1199-202. doi: 10.1056/NEJM197306072882302. No abstract available.
Results Reference
background
PubMed Identifier
14228531
Citation
ELRICK H, STIMMLER L, HLAD CJ Jr, ARAI Y. PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. J Clin Endocrinol Metab. 1964 Oct;24:1076-82. doi: 10.1210/jcem-24-10-1076. No abstract available.
Results Reference
background
PubMed Identifier
3522621
Citation
Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986 Aug;63(2):492-8. doi: 10.1210/jcem-63-2-492.
Results Reference
background
PubMed Identifier
23057765
Citation
Gunnerud U, Holst JJ, Ostman E, Bjorck I. The glycemic, insulinemic and plasma amino acid responses to equi-carbohydrate milk meals, a pilot- study of bovine and human milk. Nutr J. 2012 Oct 12;11:83. doi: 10.1186/1475-2891-11-83.
Results Reference
background
PubMed Identifier
22647249
Citation
Salehi A, Gunnerud U, Muhammed SJ, Ostman E, Holst JJ, Bjorck I, Rorsman P. The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on beta-cells. Nutr Metab (Lond). 2012 May 30;9(1):48. doi: 10.1186/1743-7075-9-48.
Results Reference
background
PubMed Identifier
19036562
Citation
Chen Q, Reimer RA. Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitro. Nutrition. 2009 Mar;25(3):340-9. doi: 10.1016/j.nut.2008.08.012. Epub 2008 Nov 26.
Results Reference
background
PubMed Identifier
25639649
Citation
Tuma P, Gojda J. Rapid determination of branched chain amino acids in human blood plasma by pressure-assisted capillary electrophoresis with contactless conductivity detection. Electrophoresis. 2015 Aug;36(16):1969-75. doi: 10.1002/elps.201400585. Epub 2015 Apr 8.
Results Reference
background
PubMed Identifier
24677638
Citation
Tuma P. Rapid determination of globin chains in red blood cells by capillary electrophoresis using INSTCoated fused-silica capillary. J Sep Sci. 2014 Apr;37(8):1026-32. doi: 10.1002/jssc.201400044. Epub 2014 Mar 13.
Results Reference
background
PubMed Identifier
4639019
Citation
Rocha DM, Faloona GR, Unger RH. Glucagon-stimulating activity of 20 amino acids in dogs. J Clin Invest. 1972 Sep;51(9):2346-51. doi: 10.1172/JCI107046.
Results Reference
background
PubMed Identifier
26007339
Citation
Pedroso JA, Zampieri TT, Donato J Jr. Reviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose Homeostasis. Nutrients. 2015 May 22;7(5):3914-37. doi: 10.3390/nu7053914.
Results Reference
background
PubMed Identifier
783201
Citation
Palmer JP, Benson JW, Walter RM, Ensinck JW. Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest. 1976 Sep;58(3):565-70. doi: 10.1172/JCI108502.
Results Reference
background
PubMed Identifier
19915164
Citation
Vahl TP, Drazen DL, Seeley RJ, D'Alessio DA, Woods SC. Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology. 2010 Feb;151(2):569-75. doi: 10.1210/en.2009-1002. Epub 2009 Nov 13.
Results Reference
background
PubMed Identifier
25560206
Citation
Marina AS, Kutina AV, Shakhmatova EI, Balbotkina EV, Natochin YV. Stimulation of glucagon-like peptide-1 secretion by water loading in human. Dokl Biol Sci. 2014 Nov;459:323-5. doi: 10.1134/S0012496614060027. Epub 2015 Jan 6. No abstract available.
Results Reference
background
PubMed Identifier
16380493
Citation
Yang J, Wong RK, Park M, Wu J, Cook JR, York DA, Deng S, Markmann J, Naji A, Wolf BA, Gao Z. Leucine regulation of glucokinase and ATP synthase sensitizes glucose-induced insulin secretion in pancreatic beta-cells. Diabetes. 2006 Jan;55(1):193-201.
Results Reference
background
PubMed Identifier
12610012
Citation
van Loon LJ, Kruijshoop M, Menheere PP, Wagenmakers AJ, Saris WH, Keizer HA. Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes Care. 2003 Mar;26(3):625-30. doi: 10.2337/diacare.26.3.625.
Results Reference
background
PubMed Identifier
18514633
Citation
Solerte SB, Fioravanti M, Locatelli E, Bonacasa R, Zamboni M, Basso C, Mazzoleni A, Mansi V, Geroutis N, Gazzaruso C. Improvement of blood glucose control and insulin sensitivity during a long-term (60 weeks) randomized study with amino acid dietary supplements in elderly subjects with type 2 diabetes mellitus. Am J Cardiol. 2008 Jun 2;101(11A):82E-88E. doi: 10.1016/j.amjcard.2008.03.006.
Results Reference
background
PubMed Identifier
28595189
Citation
Gojda J, Strakova R, Plihalova A, Tuma P, Potockova J, Polak J, Andel M. Increased Incretin But Not Insulin Response after Oral versus Intravenous Branched Chain Amino Acids. Ann Nutr Metab. 2017;70(4):293-302. doi: 10.1159/000475604. Epub 2017 Jun 9.
Results Reference
derived
Learn more about this trial
Incretin Effects of Branched Chain Amino Acids
We'll reach out to this number within 24 hrs